Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 5/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | RGS12 | O14924 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL3639234 | 0.98 | CYP1A2 (0.43) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| Water SCHEMBL1507364 | 0.98 | CYP1A2 (0.43) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| Histidine SCHEMBL5134200 | 0.84 | CYP3A4 (0.67) | SLC7A5CYP3A4CPB2HIF1A | |
| SCHEMBL17224471 | 0.83 | CYP1A2 (0.44) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL358922 | 0.83 | CYP1A2 (0.44) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL27974517 | 0.83 | CYP1A2 (0.46) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| Hydrochloric Acid SCHEMBL14831326 | 0.82 | CYP1A2 (0.43) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL4726518 | 0.81 | CYP1A2 (0.45) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL44187 | 0.81 | CYP1A2 (0.45) | CYP1A2SLC7A5PKMALPIPTGS1 | |
| SCHEMBL4727798 | 0.81 | CYP1A2 (0.45) | CYP1A2SLC7A5PKMALPIPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 936 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099159-A1 | ADHESIVE DEVICE COMPRISING AN ELECTRO-RESPONSIVE ADHESIVE ABLE TO LOWER ENVIRONMENTAL LOAD | TESA SE (DE) | 2026-05-15 | — | — | WO | claimed |
| EP-3849518-B1 | CSF-1R ANTIBODY FORMULATION | HOFFMANN LA ROCHE (CH) | 2026-03-18 | — | — | EP | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| CN-120054626-A | Solid Lewis acid catalyst and preparation method and application thereof | 四川大学 | 2025-05-30 | — | — | CN | claimed |
| CN-120022522-A | Drug-loaded microneedle, drug-loaded microneedle patch and electrically-controlled drug release microneedle system | 成都邦迈医创科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| CN-119857138-A | CSF-1R antibody formulations | 豪夫迈·罗氏有限公司 | 2025-04-22 | — | — | CN | claimed |
| EP-3714902-B1 | STABILIZATION OF PHARMACEUTICAL COMPOSITIONS COMPRISING POLYSORBATE | LEK PHARMACEUTICALS (SI) | 2024-08-28 | — | — | EP | claimed |
| CN-118356487-A | CSF-1R antibody formulations | 豪夫迈·罗氏有限公司 | 2024-07-19 | — | — | CN | claimed |
| EP-4104859-B1 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF | GENENTECH INC (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4108259-B1 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF | GENENTECH INC (US) | 2024-01-03 | — | — | EP | claimed |
| US-20090214522-A1 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF | GENENTECH, INC. (US) | 2009-08-27 | — | — | US | claimed |
| CN-100448440-C | Protective solution for preventing local ischemic damage | FRANTZ KOLER DR CHEMICAL GMBH (DE) | 2009-01-07 | — | — | CN | claimed |
| WO-2008107908-A1 | COMPOSITIONS COMPRISING PEG- INTERFERON ALPHA CONJUGATES AND RAFFINOSE AS CRYOPROTECTANT | CADILA HEALTHCARE LIMITED (IN) | 2008-09-12 | — | — | WO | claimed |
| WO-2008062481-A2 | FORMULATIONS OF PEG-INTERFERON ALPHA CONJUGATES | CADILA HEALTHCARE LIMITED (IN) | 2008-05-29 | — | — | WO | claimed |
| US-20070237762-A1 | Process for Concentration of Antibodies and Therapeutic Products Thereof | GENENTECH, INC. (US) | 2007-10-11 | — | — | US | claimed |
| EP-1786830-A2 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF | Genentech, Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| WO-2006031560-A2 | PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF | GENENTECH, INC. (US) | 2006-03-23 | — | — | WO | claimed |
| US-20060051347-A1 | Process for concentration of antibodies and therapeutic products thereof | NOVARTIS AG (CH) | 2006-03-09 | — | — | US | claimed |
| CN-1480132-A | Protective solution for preventing local ischemic damage | �����ġ����ղ�ʿ��ѧ����˾ | 2004-03-10 | — | — | CN | claimed |
| US-4415556-A | ANTIISCHEMIC AGENTS CONTAINING ALPHA-KETOGLUTARIC ACID; SURGERY; TRANSPLANTS | DR. FRANZ KOHLER CHEMIE GMBH (DE) | 1983-11-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | CYP1A2 4885/4885SLC7A5 157/4885PKM 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.